The progress has been scored despite persistent selling by director, Jose Berardo. On Thursday he unloaded 1.5 million shares at 3.625p. He has cut his interest to 2.92 per cent (10 million shares) from 12.5 per cent earlier this year.
The strength of the shares could indicate outside stake building. There has also been talk of an assets injection.
Alizyme, the drug tiddler which arrived in July, has experienced a difficult market life. The flotation price was cut to 55p, a level not seen since. The shares fell 11.7 per cent to 37.5p, equalling their low.Reuse content